Validating a New Writer s Cramp Scale
|First Received Date ICMJE||April 14, 2012|
|Last Updated Date||June 30, 2017|
|Start Date ICMJE||March 21, 2012|
|Primary Completion Date||Not Provided|
|Current Primary Outcome Measures ICMJE||Not Provided|
|Original Primary Outcome Measures ICMJE||Not Provided|
|Change History||Complete list of historical versions of study NCT01579266 on ClinicalTrials.gov Archive Site|
|Current Secondary Outcome Measures ICMJE||Not Provided|
|Original Secondary Outcome Measures ICMJE||Not Provided|
|Current Other Outcome Measures ICMJE||Not Provided|
|Original Other Outcome Measures ICMJE||Not Provided|
|Brief Title ICMJE||Validating a New Writer s Cramp Scale|
|Official Title ICMJE||Validating a New Writer's Cramp Scale|
- People with writer s cramp develop tightness in arm muscles and abnormal hand posture when writing, which makes writing difficult or impossible. At present, there is no suitable rating scale to measure the symptoms of or disability associated with writer s cramp. Researchers want to videotape people performing simple writing tasks. They will then compare the performance of people with writer s cramp on these tasks to those of people without writer s cramp. This information will help develop a rating scale to evaluate writer s cramp.
- To develop a new rating scale for writer s cramp.
- Individuals at least 18 years of age who have writer s cramp.
Objective: Writer s cramp (WC) causes significant discomfort and disability to those afflicted by this condition. Studies on WC have been hampered by the lack of objective, validated rating scales. In this study, we will test and validate new instruments to rate WC; the WC impairment scale (WCIS) and a new disability scale (WCDS).We will also collect exploratory data about biomechanics of the hand.
Study population: The study population will consist of 20 subjects. Ten patients with WC and 10 age and handedness matched HVs will constitute the study population.
Design: 10 patients with WC and 10 age- and handedness-matched HV will be videotaped while writing. The WCIS scores will be given to each subject by four blinded raters (Drs. Mark Hallett, Barbara Karp, Katherine Alter, and Camilo Toro) based on the videos. The patients will complete the WCDS. In addition, each individual will be asked to repeat some basic elements of the scale while writing on the screen of a tablet PC, and on the surface of a detached digitizing tablet in order to generate high temporal and spatial resolution pen tip position samples for further numerical analyses and scoring. The biomechanics of the hand will be measured using a published scale.
Outcome measures: Using the WCIS, inter and intra-rater reliability, internal consistency (Cronbach s alpha) face validity, and reproducibility will be measured in addition to other secondary outcomes. The ease of use by the raters will be assessed for each subject. Reproducibility of writing on tablet, writing on paper placed on a writing tablet, and writing on a tablet PC will be assessed. Finally, biomechanics of the hands of patients with WC will be compared with those of the unaffected healthy volunteers.
|Study Type ICMJE||Observational|
|Study Design ICMJE||Time Perspective: Prospective|
|Target Follow-Up Duration||Not Provided|
|Sampling Method||Not Provided|
|Study Population||Not Provided|
|Intervention ICMJE||Not Provided|
|Study Groups/Cohorts||Not Provided|
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
|Recruitment Status ICMJE||Completed|
|Estimated Completion Date||October 25, 2016|
|Primary Completion Date||Not Provided|
|Eligibility Criteria ICMJE||
|Ages||18 Years to 99 Years (Adult, Senior)|
|Accepts Healthy Volunteers||No|
|Contacts ICMJE||Contact information is only displayed when the study is recruiting subjects|
|Listed Location Countries ICMJE||United States|
|Removed Location Countries|
|NCT Number ICMJE||NCT01579266|
|Other Study ID Numbers ICMJE||120104
|Has Data Monitoring Committee||Not Provided|
|U.S. FDA-regulated Product||Not Provided|
|IPD Sharing Statement||Not Provided|
|Responsible Party||National Institutes of Health Clinical Center (CC) ( National Institute of Neurological Disorders and Stroke (NINDS) )|
|Study Sponsor ICMJE||National Institute of Neurological Disorders and Stroke (NINDS)|
|Collaborators ICMJE||Not Provided|
|PRS Account||National Institutes of Health Clinical Center (CC)|
|Verification Date||October 25, 2016|
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP